MARKET

ATNM

ATNM

Actinium Pharmac
AMEX
5.04
+0.46
+10.04%
After Hours: 5.01 -0.03 -0.60% 19:57 12/01 EST
OPEN
4.530
PREV CLOSE
4.580
HIGH
5.05
LOW
4.500
VOLUME
243.80K
TURNOVER
0
52 WEEK HIGH
14.70
52 WEEK LOW
4.000
MARKET CAP
138.16M
P/E (TTM)
-2.6294
1D
5D
1M
3M
1Y
5Y
Actinium Pharmac: Current report
Press release · 2d ago
Weekly Report: what happened at ATNM last week (1120-1124)?
Weekly Report · 6d ago
Weekly Report: what happened at ATNM last week (1113-1117)?
Weekly Report · 11/20 09:52
Weekly Report: what happened at ATNM last week (1106-1110)?
Weekly Report · 11/13 09:50
Actinium Pharmaceuticals’ Actimab-A: Potent Anti-Tumor Effects and Therapeutic Implications Justify a Buy Rating
TipRanks · 11/06 15:25
Actinium Presents Preclinical Data at SITC Demonstrating Actimab-A's Potential to Restore T Cell Immunity in the Solid Tumor Microenvironment Supporting Immunotherapy Combinations
PR Newswire · 11/06 12:30
Weekly Report: what happened at ATNM last week (1030-1103)?
Weekly Report · 11/06 09:51
Actinium Pharmaceuticals: The Trickle Down Continues, And I Maintain A Buy
Seeking Alpha · 11/03 22:08
More
About ATNM
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing targeted radiotherapies to deliver cancer-killing radiation with cellular level precision to treat patients with high unmet needs. The Company develops and markets medicines for relapsed or refractory cancer patients who are treated primarily in large quaternary care hospitals and their catchment areas. Its Iomab-B and Actimab-A product candidates fill the major unmet medical needs in relapsed or refractory acute myeloid leukemia (r/r AML). Iomab-B is a targeted bridging therapy that provides both disease control and conditioning in one agent. Actimab-A is a targeted therapy for fit patients that has demonstrated an impressive extension in survival in a proof-of-concept study and is poised for advanced development in collaboration with the National Cancer Institute (NCI).

Webull offers Actinium Pharmaceuticals Inc stock information, including AMEX: ATNM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATNM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ATNM stock methods without spending real money on the virtual paper trading platform.